FDA Finds No Preliminary Link Between Ozempic And Suicidal Thoughts

Topline Preliminary evidence suggests popular weight loss and diabetes drugs Wegovy and Ozempic are not linked to an increase in suicidal thoughts, the Food and Drug Administration said Thursday, the latest report indicating a connection does not exist amid probes by U.S. and European health agencies into potential side effects of the drugs.

The agency noted it couldn’t rule out that a “small risk may exist” as its probe continues. Key Facts A preliminary evaluation by the FDA has “not found evidence” that GLP 1 receptor agonist drugs—Wegovy, Ozempic and Mounjaro, among others—cause suicidal thoughts or actions, the agency said Thursday.

Because a “small number” of suicidal thoughts or actions were observed among people using the drugs, the FDA noted it could not “definitively rule out that a small risk may exist.” This is a breaking news story and will be updated..